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Abstract: Female FMR1 premutation carriers (PMC) have been suggested to be at greater risk of ill
health, in particular endocrine dysfunction, compared to the general population. We set out to review
the literature relating to endocrine dysfunction, including premature ovarian insufficiency (POI), in
female PMCs, and then to consider whether endocrine dysfunction in itself may be predictive of
other illnesses in female PMCs. A systematic review and pilot data from a semi-structured health
questionnaire were used. Medline, Embase, and PsycInfo were searched for papers concerning PMCs
and endocrine dysfunction. For the pilot study, self-reported diagnoses in females were compared
between PMCs with endocrine dysfunction (n = 18), PMCs without endocrine dysfunction (n = 14),
and individuals without the premutation (n = 15). Twenty-nine papers were identified in the review;
the majority concerned POI and reduced fertility, which are consistently found to be more common in
PMCs than controls. There was some evidence that thyroid dysfunction may occur more frequently in
subgroups of PMCs and that those with endocrine difficulties have poorer health than those without.
In the pilot study, PMCs with endocrine problems reported higher levels of fibromyalgia (p = 0.03),
tremor (p = 0.03), headache (p = 0.01) and obsessive–compulsive disorder (p = 0.009) than either
comparison group. Further larger scale research is warranted to determine whether female PMCs are
at risk of endocrine disorders other than those associated with reproduction and whether endocrine
dysfunction identifies a high-risk group for the presence of other health conditions.
Keywords: fragile X; premutation; endocrine; health; premature ovarian insufficiency
1. Introduction
Humans typically have a CGG repeat length of under 45 repeats in the 5′ untranslated region of
the fragile X mental retardation 1 (FMR1) gene. When the repeat length is expanded to between 55 and
200 repeats, an individual is classified as being an FMR1 premutation carrier (PMC) [1]. CGG repeat
lengths in the premutation range can expand further through maternal transmission; thus, female
PMCs are at risk of having a child with over 200 CGG repeats. In individuals with repeat lengths of
greater than 200, the fragile X mental retardation protein (FMRP) fails to be expressed and this results
in the neurodevelopmental disorder known as fragile X syndrome. Aside from this increased risk
of having an offspring with fragile X syndrome, being a female PMC was initially believed to have
no mental or physical health implications. This view has since been disregarded and PMCs are now
considered to be at heightened risk of developing health difficulties, most notably fragile X-associated
tremor/ataxia syndrome (FXTAS) and fragile X premature ovarian insufficiency (FXPOI), but also
potentially thyroid dysfunction, peripheral neuropathy, restless leg syndrome, fibromyalgia, migraines,
hypertension, depression, anxiety, and obsessive–compulsive disorder (OCD) [2,3].
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Much of the existing literature has focused on FXTAS; a neurological condition which typically
presents from the 5th decade of life onwards [4]. Although FXTAS is primarily associated with
tremor, ataxia, autonomic dysfunction, and cognitive decline [4,5], individuals with FXTAS have also
been found to be at higher risk of other health problems including thyroid disease, hypotension,
fibromyalgia, and possibly migraine, than those who do not have FXTAS [3,6,7]. The development
of FXTAS is proposed to be linked to an overexpression of FMR1 mRNA resulting in intranuclear
inclusions, cell toxicity [8–13], and possible mitochondrial dysfunction [14,15]. The health problems
co-occurring with FXTAS may be a direct consequence of FXTAS itself, or alternatively the presence of
FXTAS may be an indicator of a more severe pathological process affecting multiple organ systems [4,6].
The prevalence of FXTAS is only about 8.3% in female PMCs which is considerably lower than in
male PMCs (50% of 70–90 year olds) and may be attributed to the additional (unaffected) X chromosome
within females having a protective factor [7,16]. The current research, therefore, may only provide a
partial understanding of the health of female PMCs. In contrast, only females can have FXPOI, which
is an endocrine condition characterised by absent or irregular periods, and menopausal symptoms
(early menopause, hot flushes, and infertility); it has been identified that up to a quarter of PMCs
show the most severe outcome of FXPOI—premature ovarian failure (POF), usually characterized as
menopause before the age of 40 [17].
The pathology underlying FXPOI is still to be fully explained, but may be similar to that suggested
for FXTAS. As both the brain and gonads are regions in the body where FMRP is highly expressed
(and therefore FMR1 highly transcribed) [10,18], cell toxicity could account for the heightened risk
within female PMCs to develop both a neurological and a gonadal condition. Consistent with this,
post-mortem studies of PMCs have documented the presence of intranuclear inclusions in non-central
nervous system tissues, including, but not limited to, the gonads, thyroid, pituitary, and adrenal
glands [19–22]. Endocrine disorders, such as premature ovarian insufficiency (POI) and thyroid
dysfunction, may therefore represent markers of multi-system pathology in female PMCs, similar to
the findings for FXTAS. Should this be the case then their presence would be an important clinical
indicator for the need to thoroughly investigate affected individuals.
The intention of this study was therefore to review our existing knowledge around endocrine
dysfunction and the FMR1 premutation, and to consider whether or not the presence or absence
of endocrine dysfunction is associated with markers of additional physical and/or mental illness.
We initially carried out a systematic review of the literature relating to endocrine dysfunction in
PMCs and then conducted a pilot study examining the self-reported health problems in female
PMCs with endocrine dysfunction and compared these to PMCs without endocrine dysfunction and
to non-carriers.
2. Materials and Methods
2.1. Literature Review
A systematic review was conducted to investigate the effect of endocrine problems in PMCs.
All published articles indexed in Medline, Embase, and PsycInfo up to June 2016 were searched using
the terms endocrine, FXPOI, ovar$, thyroid, menopause, pituitary, adrenal, hypothalamus, parathyroid,
pineal, and pancreas; combined using an OR operator. The results were then combined using an
AND operator with all studies which concerned human females and contained the terms fragile X
or premutation. The reference lists of identified articles were also searched for articles meeting our
inclusion criteria.
All abstracts were reviewed independently by two authors (A.M. and S.E.) and articles which
were potentially suitable for inclusion were retrieved in full text and further reviewed by S.C. and
A.S. To be included in the review, studies had to be published in a peer-reviewed journal and contain
a statistical evaluation of endocrine dysfunction in a female PMC group (either within the group,
or between PMCs and controls). Papers were excluded if they were a review, or based solely on
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understanding the molecular mechanisms underlying POI. Case studies and PMC prevalence studies
within the broader population of patients with POI were also excluded.
2.2. Pilot Study
To further investigate the relationship between endocrine difficulties and health in female PMCs,
a pilot study was conducted. Thirty-two female PMCs and fifteen non-carriers (NC) were recruited
from the University of Edinburgh’s Patrick Wild Centre fragile X research registry. The fragile X
research registry is an ongoing longitudinal study which aims to determine the clinical history of
people with fragile X and the fragile X premutation. The nature of this registry means that the
non-carriers were primarily drawn from families affected by fragile X syndrome. All participants
completed a structured clinical history questionnaire. For 17 of the 32 PMCs the questionnaire was
administrated through a face-to-face interview with a clinical psychologist or consultant psychiatrist.
The remaining participants completed an online version. The online version of the questionnaire
included additional questions, asking about the presence of conditions which had been repeatedly cited
by participants during face to face interviews. Any item only listed within the online questionnaire is
marked with an asterisk (*) within this methods section.
All participants, regardless of questionnaire version used, were asked about their personal
demographics (age, gender, and FMR1 status), whether they took medication or not, and to name
the medication(s) used. Medications were subsequently grouped into one of eight categories
(cardiovascular, digestive, metabolic, endocrine, neurological, mental health, analgesic, or other),
which were confirmed by a consultant psychiatrist and a research nurse.
Participants were then asked about the function of their endocrine system (in particular the
presence of any one of: early menopause, absence of or irregular menses, or hypo-/hyperthyroidism).
The participants were also asked specific questions relating to dysfunction of other bodily systems.
The body systems asked about included cardiovascular (heart and circulatory problems*), digestive
(gastric difficulties), immune (allergies), musculoskeletal (hypermobility), sensory (hearing and vision
difficulties not corrected by glasses), neurological (epilepsy/seizures, migraines/headaches, pins and
needles/paresthesia* and FXTAS/tremor), and mental health difficulties (depression, anxiety disorders,
and obsessive compulsive disorders). They were also asked about other pain-associated conditions
(chronic pain*, arthritis*, endometriosis*, and fibromyalgia). For each condition the participant could
reply yes (if they had been officially diagnosed), possibly/unsure (if they felt the diagnosis applied to
them but had not received a formal diagnosis), or no (if the diagnosis did not apply to them). As this
was a pilot, it was deemed more important to eliminate under-reporting bias than over-reporting,
therefore, yes and maybe responses were combined together for coding. Participants only had to
report the possible presence of one condition within a given body system, to be coded as having a
potential difficulty within that body system.
All participants were asked if they experienced any other additional health problems, and these
were manually assigned by the research team to the relevant body system classification. Of note,
muscular pain was coded under pain-associated difficulties as opposed to musculoskeletal difficulties
and a new coding, respiratory, was created to incorporate any lung-related difficulties. Any unassigned
conditions remained categorized as ‘other’. The research team then counted the number of health
difficulties (excluding endocrine issues) reported by each participant; this was used as a measure of
overall health.
IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp., Armonk, NY, USA) was used for
data input and analysis. The PMCs were divided into two groups; the first group endorsed one or
more of early menopause, irregular menses, or thyroid difficulty, and were therefore classed as having
potential evidence of endocrine dysfunction; the second group did not endorse any of these conditions.
The non-carrier (NC) control group did not have fragile X syndrome or carry the premutation.
The groups were compared for age differences using a Kruskal-Wallis test. The significance level for
all analyses was set at p < 0.05.
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Fisher’s exact tests were used to compare the groups in terms of how many individuals were on
medication (2-sided) and levels of polypharmacy (as defined by taking four or more medications).
Fisher’s exact tests were also used to investigate group differences in each of the eight categories of
medication (cardiovascular, digestive, metabolic, endocrine, neurological, mental health, analgesic,
and other).
To ascertain if the endocrine group had reported significantly more health issues than the
other two groups, a Fisher’s exact test was used. The groups were then compared for differences
in reported health difficulties within each of the seven body systems (cardiovascular, digestive,
immune, muscular/skeletal, respiratory, sensory, and neurological), mental health, and pain-associated
conditions using Fisher’s exact tests. When significant differences (p < 0.05) between the groups were
found for these categories, or results were approaching significance (p < 0.1), the specific conditions
reported under each category were then compared between the groups using Fisher’s exact tests.
3. Results
3.1. Literature Review
A summary of the extraction process is given in Figure 1. Twenty-nine papers were identified
that met the inclusion/exclusion criteria.
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Figure 1. Summary of extraction process. POI: premature ovarian insufficiency.
3.1.1. Reproductive System
Table 1 summarises the studies which have considered reproductive difficulties in PMCs.
Primary Ovarian Failure/Primary Ovarian Insufficiency
Primary ovarian failure (POF)/POI are the most commonly investigated endocrine abnormalities
in female PMCs. Studies have consistently shown female PMCs to be at significantly higher risk
of experiencing POI than controls [23–25]. Female PMCs have an elevated risk of having an early
menopause compared to both females with fragile X syndrome [17,26] and NC [17,24,25,27–30].
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Table 1. Summary of studies considering reproductive health in female premutation carriers (PMCs).
Paper Groups n Mean Age Features Studied Findings
Allen et al., 2007 [23]
PMC—low repeats
PMC—mid repeats
PMC—high repeats
NC
127
237
70
521
42.7 (14.3)
45.8 (12.0)
35.8 (13.6)
56.1 (9.4)
POI
Menstrual cycle
Fertility
Obstetric features
All PMC repeat lengths significantly associated with earlier premature
ovarian failure (mid > high > low)
Low and middle sized repeats show shorter and more skipped
menstrual cycles. Mid-sized repeats showed irregular menstrual cycles.
Low repeat lengths show early menarche.
Mid-sized repeats associated with reduced fertility.
Mid-sized repeats associated with increased DZ twinning. NSD in
spontaneous abortion rates.
Allingham Hawkins et al.,
1999 [17]
PMC
FXS
NC
395
128
237
- Early menopause Increased in PMC
Chonchaiya et al., 2010 [31]
PMC w parent w
FXTAS
NC
110
43
44.8 (8.2)
43.8 (8.1)
POI
Menopausal symptoms
Infertility
NSD
Increased in PMC
NSD
Coffey et al., 2008 [7]
PMC w FXTAS
PMC w/o FXTAS
NC
15
63
36
-
-
-
POI NSD regardless of FXTAS status
Elizur et al., 2014 [32] PMCNC
21
15
31.5 (3.4)
30.8 (4.3)
Response to controlled
ovarian hyperstimulation
PMC had higher FSH:LH and gonadotrophin dosage and fewer
retrieved oocytes.
Number of retrieved oocytes showed non-linear association with repeat
number and negative correlation with granulosa cell
FMR1 mRNA in PMCs.
Ennis et al., 2006 [33] PMC 45 - Early menopause Curvilinear association with CGG number
Hall et al., 2016 [34] PMCNC
33
13
54.2 (16.8)
47.0 (10.1) Ovarian dysfunction NSD
Hundscheid et al., 2000 [35] PMC (paternal origin)PMC (maternal origin)
82
27
-
- Early menopause/POI Earlier/increased in PMC with paternally inherited mutation
Hundscheid et al., 2001 [36]
PMC not on OCP
NC/FXS not on OCP
PMC on OCP
NC/FXS on OCP
17
28
13
21
36 (2.2)
34 (4.7)
34 (5.3)
31 (4.5)
FSH
Inhibin B
17β oestradiol
Higher in PMC regardless of contraceptive use
NSD
NSD
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Table 1. Cont.
Paper Groups n Mean Age Features Studied Findings
Hundscheid et al., 2003 [30] PMCNC
152
112
52.7 (13.5)
41.1 (12.5)
Early menopause/POI
Obstetric features
Increased in PMC
NSD in number of pregnancies, children, spont.
abortion, fetal loss or twinning
Hunter et al., 2008 [29]
PMC—low repeats
PMC—mid repeats
PMC—high repeats
NC
134
248
78
541
49.1 (15.9)
43.3 (12.6)
38.8 (11.7)
42.4 (15.9)
Early menopause
Compared to NC, rates of early menopause highest in with mid-sized
repeats (4x) then high and low sized repeats (2x). Significant genetic
component to age of menopause even after controlling for PMC status.
Mailick et al., 2014 [37] Postmenopausal PMC 88 - Age at menopause Curvilinear association between age at menopause and repeat length.NS relationship between menopause age and X inactivation ratio.
Mallolas et al., 2001 [38]
PMC w POI/early
menopause
PMC w/o POI/early
menopause
21
206
-
-
Parental origin of
mutation NSD
Murray et al. 1999 [39] PMCNC/FXS
19
32 FSH Increased FSH levels in PMC group
Murray et al., 2000 [28] PMCNC/FXS
116
236 -
Early menopause
Obstetric features
Inhibin
Menopause occurs at significantly younger age in PMC. Repeat size and
skewed X inactivation not related to age of menopause.
Subset showed NSD in twinning or unfavourable pregnancy outcome.
No relationship between repeat size and inhibin concentrations in PMC.
Rodriguez-Revenga et al.,
2009 [40]
PMC w POI
PMC w/o POI
NC
40
220
220
- POI No relationship between skewed X-inactivation and POI.
Rohr et al., 2008 [41] PMC < 70 repeatsPMC > 70 repeats
-
-
18–50
18–50
FSH
AMH
PMC with >70 repeats had higher FSH levels than those
with <70 repeats in 31–40 year old age group
PMC with >70 repeats had higher AMH levels than those
with <70 repeats in all age groups tested
Schwartz et al., 1994 [27]
PMC
FXS
NC (relatives)
NC (non-relatives)
92
39
109
50
46
33
37
33
Menstrual cycle
Early menopause
Gynaecological
complications
Spontaneous abortions
More irregular in PMC
Increased in PMC
Increased in PMC compared to related NCs
NSD
Spath et al., 2010 [42]
PMC w POI
PMC w/o POI
NC w POI
37
64
25
45.9 (13.2)
47.1 (12.7)
31.7 (19.5)
POI No relationship between skewed X-inactivation and POI
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Table 1. Cont.
Paper Groups n Mean Age Features Studied Findings
Spath et al., 2011 [43] PMCNC
517
551
51.5
53.5 Age at menopause
Within PMC, age at menopause significantly predicted using
multivariate analysis by CGG repeat length, mean menopausal age of
first degree relatives and smoking. CGG repeat length showed
non-linear relationship with risk increased between 62 and 120 repeats.
Sullivan et al., 2005 [24] * PMCNC
183
324
44.3 (13.5)
42.3 (14.6)
POI/early menopause
FSH
PMC at increased risk of POI and early menopause compared to NC;
highest rates with mid-sized repeat lengths; no association between
POI/early menopause and parental origin.
Subgroup showed no increase in FSH in PMC but further sub-analysis
showed increased levels in PMC aged 30–39 years old. No relationship
between FSH and repeat length, X inactivation ratio or parental origin.
Tejada et al., 2008 [44] PMC w POIPMC w/o POI
25
17
-
- POI
NSD in mRNA, X inactivation ratio and CGG repeat lengths.
POI associated most with >100 repeats.
Vianna-Morgante et al.,
1999 [25]
PMC
FXS
NC
101
37
55
43.3 (11.8)
36.6 (9.4)
40.4 (12.7)
Early menopause/POI PMC at increased risk of early menopause compared to FXS and NC.No relationship between POI and parental origin.
Welt et al., 2004 [45] PMCNC
11
22
34.5 (5.7)
34.6 (5.8)
Menstrual cycle
FSH
LH
Inhibin A
Inhibin B
Oestradiol
Progesterone
Reduced total cycle length in PMC driven by reduced follicular phase
Increased in PMC throughout follicular and luteal phases
NSD
Decreased in PMC in early and mid-luteal phases
Decreased in PMC in early and mid-follicular and early luteal phases
NSD
Decreased in PMC in follicular phase
Wheeler et al., 2014 [46] PMC w POIPMC w/o POI
73
365
48.6 (11.7)
48.9 (12.2)
Menstrual cycle
Fertility
Obstetric features
POI associated with absent or irregular menstrual periods
POI associated with greater use reproductive assistance/fertility drugs
POI associated with lower rates of precipitous labour (under 2 h)
Age is given as mean (standard deviation); PMC, premutation carriers; NC, non-carriers; FXS, fragile X syndrome; FXTAS, fragile X associated tremor ataxia syndrome; POI, premature
ovarian insufficiency; NSD, no significant difference; FSH, follicular stimulating hormone; LH, luteinizing hormone; OCP, oral contraceptive pill; AMH, anti-müllerian hormone;
MZ, monozygotic; DZ, dizygotic.
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Premenopausal Ovarian Dysfunction
Evidence of ovarian dysfunction has also been identified in premenopausal PMCs, including
shorter and more irregular menstrual cycles [3,23,27,45] and aberrant ovarian hormone levels.
Follicular stimulating hormone (FSH) has been shown to be increased [36,39,45], with one study
suggesting that this is mainly the case for PMCs between 30 and 39 years of age [24]; the latter study
also suggested that anti-müllerian hormone (AMH) may be a more sensitive measure of ovarian
dysfunction in PMCs as significant differences in AMH existed across all age groups. Differences in
oestradiol have not been identified [36,45] while the levels of inhibin A and B may be reduced, but only
in certain phases of the menstrual cycle [45]. As might be expected, the later development of POI has
been linked to increased rates of uptake of fertility assistance, which are higher among PMCs with
POI, compared to those without POI [46]. PMCs have also been observed to show a reduced response
to ovarian hyperstimulation compared to the typical population [32].
Relationship with Genetic Characteristics
Several studies have focused on determining whether CGG repeat length was a risk factor in
developing endocrine related health difficulties, and the focus of these studies has predominately
been on menopause. Initial studies failed to find a significant correlation between CGG repeat
length and the age of menopause [38]. However, one study found that the age of menopause only
became associated with repeat size when individuals with high repeat numbers were excluded (over
100 repeats), and proposed that there was a curvilinear association between CGG repeat length and
the age of menopause with the greatest risk occurring for those with medium length repeats [24].
This has since been confirmed by a number of further studies [29,33,37,44] and also extended to include
premenopausal menstrual dysfunction [23]. The exact repeat length of greatest risk is not clear, with
some studies suggesting that it is in the region of 80–100 repeats [23], whereas others finding that it
may be slightly lower [33] or higher [37,44] than this.
The pattern of X chromosome inactivation (XCI) and the parental origin of the premutation have
also been considered as potential risk factors for developing POI. One study has shown a significant
relationship between paternally inherited mutations and early menopause/POI [35], while others have
not found such a relationship [24,25,42]. No compelling evidence has been found for a relationship
between skewed XCI in the development of POI [24,37,40,42,44].
3.1.2. Other Endocrine Disorders
Table 2 summarises the studies which have considered other endocrine disorders in female PMCs.
The most commonly investigated endocrine disorders in female PMCs, other than POI, are thyroid
disease and type II diabetes.
Several studies have reported that female PMCs do not show any increase in thyroid dysfunction
although non-significant increases were generally identified [6,30,34]. Hunter et al. [6] did find that the
presence of irregular menstruation is significantly associated with the presence of thyroid dysfunction.
Coffey et al. [7] have identified that female PMCs with FXTAS had significantly higher rates of thyroid
problems than controls (50% vs. 15.4%). Within this study, two thirds (n = 6) had hypothyroidism of an
unspecified etiology and one third had hyperthyroidism. Winarni et al. [48] reported similar increases
when considering autoimmune thyroid disease in PMCs with FXTAS. It is also important to note that
in several studies the incidence of thyroid disease reported in the control populations was higher than
the expected population prevalence, which may have minimised differences [34,47].
With regard to diabetes, no study has identified a significant difference in the prevalence of
diabetes or pre-diabetes between female PMCs and controls [6,7,30,34].
One study has considered other markers of endocrine dysfunction, specifically pituitary or adrenal
dysfunction, and salivary cortisol levels [34]. No significant differences were found between the groups,
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although it is worth noting that no cases of pituitary or adrenal dysfunction were found in either the
PMCs or controls.
Table 2. Summary of studies considering non-reproductive endocrine issues in PMCs.
Paper Groups n Mean Age Features Studied Findings
Chonchaiya et al.,
2010 [31]
PMC w parent w FXTAS
NC
110
43
44.8 (8.2)
43.8 (8.1)
Thyroid disease
Diabetes
NSD
NSD
Coffey et al.,
2008 [7]
PMC w FXTAS
PMC w/o FXTAS
NC
18
127
69
59.2 (10.3)
42.3 (11.5)
45.8 (14.9)
Thyroid disease
Type II diabetes
Increased only in PMC w
FXTAS when compared
to subset of age matched
controls (57.1 years old)
NSD
Hall et al., 2016 [34] PMCNC
33
13
54.2 (16.8)
47.0 (10.1)
Thyroid disease
Pituitary/adrenal
dysfunction
Thyroid antibodies
Low 8 a.m. cortisol
Prediabetes
NSD
None detected in either
group
NSD
NSD
NSD
Hundscheid et al.,
2003 [30]
PMC
NC
152
112
52.7 (13.5)
41.1 (12.5)
Thyroid disease
Type II diabetes
NSD
NSD
Hunter et al.,
2010 [6]
PMC
NC
203
334
37.1 (8.4)
32.5 (10.1)
Thyroid disease
Type II diabetes
NSD. Presence of
irregular menstruation
significantly associated
with presence of thyroid
problems
NSD
Winarni et al.
(2012) [47]
PMC w FXTAS
PMC w/o FXTAS
NC
PMC w FXTAS
PMC w/o FXTAS
NC
PMC w POI
PMC w/o POI
NC
56
288
72
45
158
57
41
147
50
-
-
-
>40
>40
>40
>40
>40
>40
Autoimmune
thyroid disease
PMC w FXTAS > PMC
w/o FXTAS = NC
PMC w FXTAS > PMC
w/o FXTAS = NC
NSD
Age is given as mean (standard deviation).
3.1.3. Association between Endocrine Dysfunction and Other Health Conditions
Table 3 summarises those studies which have considered the relationship between endocrine
dysfunction and health difficulties in female PMCs.
The available research only considers the association between POI or early menopause and
non-reproductive health difficulties experienced by PMCs, i.e., there are no studies to date which
have considered whether those with other endocrine disorders are at greater risk of health problems.
Wheeler et al. [46] found that PMCs with POI were at increased risk of muscle weakness, dizziness,
and nausea. Winarni et al. [47] found that compared to those without POI and to controls, PMC with
POI have higher total rates of any immune-mediated disorders (defined in this study as including
autoimmune thyroid disease, fibromyalgia, irritable bowel syndrome, Raynaud’s phenomenon,
rheumatoid arthritis, Sjögren syndrome, lupus, multiple sclerosis, and optic neuritis). Three studies
have investigated the effects of ovarian dysfunction on anxiety and depression and none has reported
significant relationships [6,48,49], although Roberts et al. found a trend towards a significant
relationship between POI and depression [49].
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Table 3. Summary of studies considering co-occurring health difficulties in female PMCs with
endocrine dysfunction.
Paper Groups n Mean Age Features studied Findings
Hunter et al.,
2010 [6]
PMC
NC
203
334
37.1 (8.4)
32.5 (10.1)
Anxiety
Depression
Ovarian reserve did not predict either
depression or anxiety in PMCs
Kenna et al.,
2013 [48]
Premenopausal PMC
Perimenopausal PMC
Postmenopausal PMC
17
7
22
46.2 (6.2)
43.7 (5.7)
50.1 (4.1)
Anxiety
Depression
NSD between groups; no significant
relationship between prevalence of
anxiety or depression and age of
menopause or postmenopausal use of
HRT
Roberts et al.,
2016 [49]
PMC w/POI
PMC w/o POI
34
49
-
-
Anxiety
Depression
POI did not significantly predict
anxiety
POI showed trend towards
significantly predicting depression
Wheeler et al.,
2014 [46]
PMC w POI
PMC w/o POI
73
365
48.9 (12.2)
48.6 (11.7)
Anxiety
Depression
ADHD
Learning disability
Speech/language dis.
Hypertension
Heart disease
Diabetes
Autoimmune disorder
Thyroid disease
GI problems
Seizures
Specific physical
symptoms
NSD
NSD
NSD
NSD
NSD
NSD
NSD
NSD
NSD
NSD
NSD
NSD
PMC with POI reported significantly
more muscle weakness, dizziness and
nausea
Winarni et al.
(2012) [47]
PMC w POI
PMC w/o POI
NC
41
147
50
>40
>40
>40
Immune mediated
disorders PMC w POI > PMC w/o POI > NC
Age is given as mean (standard deviation); GI, gastrointestinal; HRT, hormone replacement therapy.
3.2. Pilot Study
There were no significant differences in mean age between the groups: endocrine PMC (n = 18;
47.7 years, standard deviation (SD) = 13.6), non-endocrine PMC (n = 14; 44.4 years, SD = 11.5), and the
controls (n = 15; 42.0 years, SD = 11.5) (p = 0.33); 44% of the endocrine group, 50% of the non-endocrine
PMC group, and all of the controls completed the online version of the questionnaire.
A summary of the results is given in Table 4. The endocrine PMC group reported having
significantly more health problems overall than both the non-endocrine PMC and the control groups
(p = 0.040) (Table 3). They were over three times more likely (44.4%) to report experiencing four or more
health problems than controls (13.3%) and over six times more likely than PMCs without endocrine
difficulties (7.1%).
PMCs with endocrine difficulties were significantly more likely to report a neurological issue than
either the PMC non-endocrine or the control group (72.2% vs. 28.6% vs. 46.7%, respectively, p = 0.049,
Table 4). Analysis of the sub-type of neurological issues reported revealed that only the endocrine
group reported experiencing tremor (22.2%; p = 0.03) and that the rate of headache/migraine for both
the endocrine (55.6%) and NC (46.7%) was higher than for PMCs without endocrine problems (7.1%)
(p = 0.01; Table 4).
No significant differences were found in overall mental health although there was a non-significant
trend towards a difference between the groups (p = 0.06; Table 4). The groups were however
significantly different in their reporting of having a diagnosis of OCD. The PMC endocrine group
(44.4%) was significantly more likely to report having symptoms than either of the other two groups
(0% and 23.1%; p = 0.009). There was also a weak trend towards a significant difference in reported
anxiety/depression (p = 0.097).
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Table 4. Physical and mental health issues in PMC.
Group Endocrine Non-endocrine
Analysis PMC PMC NC p
% n = 18 % n = 14 % n = 15
Medication
Takes medication 61.1 18 50 14 28.6 14 0.20
Number of medications taken
0–3 72.2 18 92.9 14 85.7 14
3+ 27.8 7.1 14.3 0.30
Type of medication used
Cardiovascular 0 17 7.2 14 7.1 14 0.52
Digestive 38.9 18 21.4 14 13.3 15 0.26
Metabolic 5.9 17 7.1 14 7.1 14 1.00
Endocrine 17.6 18 0 14 0 15 0.10
Neurological 11.8 18 14.3 14 0 15 0.44
Mental health 29.4 18 21.4 14 14.3 14 0.61
Analgesic 29.4 18 7.1 14 0 15 0.04 *
Other 23.5 18 21.4 14 7.1 14 0.50
Health difficulties
Number of health difficulties 18 15
0–3 55.6 92.9 14 86.7
4+ 44.4 7.1 14 13.3 0.04 *
Cardiovascular 27.8 18 7.1 14 13.3 15 0.36
Digestive 38.9 18 21.4 14 13.3 15 0.26
Immune 22.2 18 21.4 14 26.7 15 1.00
Muscular/skeletal 27.8 18 7.1 14 20.0 15 0.38
Respiratory 5.6 18 14.3 14 0 15 0.38
Sensory 27.8 18 14.3 14 33.3 15 0.54
Neurological 72.2 18 28.6 14 46.7 15 0.049 *
Tremor 22.2 18 0 14 0 15 0.03 *
Headache 55.6 18 7.1 14 46.7 15 0.01 *
Paraesthesia 22.2 18 0 14 6.7 15 0.17
Seizures 5.6 18 23.1 13 0 15 0.09
Mental health 77.8 18 35.7 14 66.7 15 0.06
Anxiety/depression 58.8 17 35.7 14 71.4 14 0.19
OCD 44.4 18 0 14 23.1 13 0.009 *
Pain-associated conditions 55.6 18 14.3 14 26.7 15 0.045 *
Arthritis 16.7 18 0 14 20.3 15 0.29
Fibromyalgia 22.2 18 0 14 0 15 0.03*
Endometriosis 0 18 0 14 0 15 N/A
* Significant at p < 0.05 level; n = number of participants who completed each section of the questionnaire.
OCD, obsessive–compulsive disorder.
A higher number of PMCs in the endocrine group reported experiencing pain-associated
conditions (55.6%, p = 0.045; Table 3) than the controls (14.3% and 26.7%). This was also reflected
in medication use, with greater use of analgesic medication reported by endocrine PMCs (29.4%)
compared to the non-endocrine PMCs (7.1%) and the controls (0%) (p = 0.04). When the individual
pain-related conditions were investigated, fibromyalgia was only reported by the PMCs with endocrine
difficulties (22.2%; p = 0.03), whereas no significant differences were found in the reported rate of
arthritis between groups.
4. Discussion
4.1. Current Findings
We have identified that female PMCs with co-existing endocrine dysfunction are more likely to
report having multiple health difficulties than those without endocrine dysfunction and non-carrier
controls. Specifically, we identified clearly increased rates of fibromyalgia, headache, and tremor, as
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well as some evidence of increased levels of mental health difficulties. Analgesic use was also reported
to be increased in PMCs with endocrine dysfunction.
The association between endocrine dysfunction and tremor is consistent with earlier corollary
findings of abnormal endocrine tissue in PMCs with FXTAS [19,22]. Similarly, we also identified
increased rates of fibromyalgia in PMCs with endocrine dysfunction, but not in those who do not
show endocrine dysfunction. Although Winarni et al. [47] did not find such a relationship, increased
rates of fibromyalgia have previously been reported in female PMCs more generally [7]. It has been
suggested that this may result from increased levels of FMR1 mRNA leading to alterations in pain
neurotransmission in female PMCs [50]. It is possible, therefore, that endocrine dysfunction is an
early marker of future FXTAS and of peripheral nervous system damage, manifesting as fibromyalgia.
This altered neurotransmission may also be responsible for the increased levels of headache that we
report, although it has also been suggested previously that there may be a more direct link between
mitochondrial dysfunction and a susceptibility to migraines in PMCs [18]. Regardless, our data
suggests that the identification of endocrine dysfunction in PMCs should prompt detailed assessment
of neurological symptoms, including headache, and rheumatological pain.
Somewhat in contrast to Hunter et al. [6] and Kenna et al. [48] we also identified some evidence of
increased levels of mental health difficulties, particularly when comparing the PMC groups with and
without endocrine dysfunction. These differences were less apparent when the endocrine PMCs were
compared to controls, although it is notable the control group in our study reported very high rates
of mental health difficulties which may have obscured greater differences between the groups. It is
also important to note that the age of participants may have obscured differences in our pilot study
as depressive and anxiety disorders had been found to have a later onset in PMCs compared to the
general population [51]. The high rates of OCD which we report in those with endocrine dysfunction
have previously been identified in female PMCs [52] and are reported to be associated with increased
levels of FMR1 mRNA in PMCs more generally [53], but no other study has considered whether they
relate specifically to endocrine dysfunction.
The current study is unable to address the mechanism accounting for the association between
endocrine dysfunction in female PMCs and ill health that we report. It is possible that the FMR1
premutation is associated with a multi-system pathological process, with the same or similar
mechanisms occurring in different organ systems. Previous studies identifying intranuclear inclusions
across multiple systems are in keeping with this theory [19–22]. Alternatively, it is possible that the
health problems faced by PMCs are mediated by endocrine dysfunction and are not a direct effect of
the premutation. To determine which of these is the case, future work should include an additional
comparator group consisting of non-carriers with endocrine dysfunction to establish whether PMCs
have a particular illness profile.
4.2. Limitations of Existing Research
The primary limitation of the existing research, including our own pilot, is the reliance on
self-reported measures. These have provided useful insights and a foundation for further study
but they are also open to recall and reporting bias. Reporting of an illness may also be affected by
medication use, either increasing the likelihood that a condition is recalled and therefore reported, or
decreasing the symptoms of a condition leading to under-reporting. As Hunter et al. [29] highlighted,
this may be particularly true for menopausal symptoms as these are likely to have occurred many
years before and may be masked by hormone replacement or birth control medications. Interestingly,
Hunter et al. [29] also used both self-report of symptoms in combination with clinical examination and
standardized scales and found certain symptoms to be under-reported while others were over-reported
compared to the more standardised measures. Future research should employ standardised measures
of data collection, including the use of health and prescription records to minimise bias.
Much of the existing endocrine-related research in PMCs has focused upon reproductive
difficulties, with only a few studies examining diabetes and thyroid dysfunction and none investigating
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other endocrine disorders. Similarly, the relationship between endocrine dysfunction and other health
conditions is relatively under-investigated, particularly compared to the large body of literature
pertaining to the comorbidities associated with FXTAS. FMR1 mRNA is widely transcribed in many
tissues throughout the body and as such one would predict that dysfunction of other bodily systems
may be associated with endocrine dysfunction.
Similarly, although our pilot data showed some clear results, it was also constrained by the
limitations evident in the rest of the literature. In addition, as it was a pilot study, the sample size was
small and we did not correct for multiple comparisons, meaning that significant associations may have
been missed or overestimated. The small nature of the sample meant that we were unable to separate
non-carriers into those with and without endocrine problems, meaning that this may have minimized
differences between the groups. The questionnaire was administered in two slightly different formats,
which may also have introduced bias. Furthermore, we did not include specific questions around the
use of fertility assistance or difficulties conceiving. Our control group had high levels of mental health
disorders in particular which may have obscured some results; this group was likely to consist of
parents and family members of individuals with fragile X and therefore may have had higher levels of
parenting stress than a population control group. Finally, we did not collect biological variables, such
as CGG repeat number or FMR1 mRNA levels, and are therefore unable to relate these to morbidity.
5. Conclusions
This paper has highlighted that FMR1 PMCs with endocrine issues appear to be at significant
risk of wider health difficulties, compared to those without evidence of endocrine dysfunction.
They therefore represent a group in which detailed physical and mental health examination should be
conducted. Future studies with large populations of female PMCs, using comprehensive clinical and
biochemical examination and/or the use of health records, as opposed to solely self-report measures are
required. The inclusion of a non-carrier group matched for endocrine dysfunction would be important
in future research to determine whether the high rates of comorbid illness that we report in PMC with
endocrine dysfunction are primarily related to PMC status per se, or are a secondary consequence of
endocrine dysfunction regardless of cause. Potential confounding factors also need to be taken into
account, such as the presence of a child with fragile X syndrome in the family. Further research at
multiple levels of investigation from cellular to health behavior is strongly recommended to understand
the profile of these females and inform genetic counselling, medical assessment and intervention.
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